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Progression and Regression of Coronary
Atherosclerosis Occur within the Same Patient
During Placebo Treatment and During Lipid-Lowering
Therapy with Pravastatin
4:30
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Conclusion: significant progression and regression of CA within the same
patient occurred in 41 (13%) PRAY-patients and in 27 (9%) PLAC-patients.
Thus, although pravastatin slows mean progression of CA, progression and
regression of CA within the same patient still occurs in a considerable num-
ber of patients during lipid lowering therapy.
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endpoints were OCA assessments of 1. change in Mean Segment Diameter
(MSD) averaged per patient and 2. change in Minimum Obstruction Diameter
(MOD) averaged per patient.
Results: 77B patients (BB%) of the patients had an evaluable final an-
giogram. Mean Segment Diameter decreased with 0.10 mm in the placebo
group versus 0.06 mm in the pravastatin group (p = 0.019): the mean differ-
ence between treatment groups was 0.04 mm with 95% confidence interval
(ei) of 0.01-0.07 mm. The median Minimum Obstruction Diameter decreased
with 0.09 mm in the placebo group versus 0.03 mm in the pravastatin group
(p = 0.001): the difference of the medians between the treatment groups
was 0.06 mm with ei of 0.02-o.0B mm. At the end of the follow-up period
89% (ci B6-92%) of the pravastatin patients and 81 % (ei 77-85%) of the
placebo patients were without new cardiovascular events (p = 0.002).
Conclusions: in symptomatic men with normal or moderately raised serum
cholesterol, pravastatin slows progression of coronary atherosclerosis and
reduces the number of cardiovascular events.
J. Wouter Jukema. Ad J. van Boven, Johan H.C. Reiber. Aeilko H. Zwinderman.
Albert VG. Bruschke. REGRESS study group Interuniversity Cardiology Institute,
Utrecht The Netherlands
REGRESS (Regression Growth Evaluation Statin Study) is a placebo con-
trolled multicenter study to asses the effect of 2-yr treatment with Pravas-
tatin (PRAV) on progression and regression of angiographically documented
coronary atherosclerosis (CA) in patients with a serum cholesterol between
4--B mmol~ (155-310 mg/dl). Analyses of the coronary arteriograms were
performed by quantitative computer analysis. The primary endpoints of the
study, change in Mean Segment Diameter and Minimum Obstruction Diam-
eter (MOD) averaged per patient, showed significant retardation of mean
progression of CA in the PRAY-group as compared to the placebo (PLACj-
group. However, these mean changes per treatment group are hardly infor-
mative about individual CA-behavior. Therefore we determined for all 641
patients included in the primary MOD-analysis: 1. a mean progression score
(MPS)-cumulative value of all >0.4 mm progressing obstructions divided by
the number of contributing obstructions-, and 2. a mean regression score
(MRSj-cumulative value of all >0.4 mm regressing obstructions divided by
the number of contributing obstructions. Obstructions changing :::,:0.4 mm
were considered stable and do not contribute to the scores. Thus, each pa-
tient is characterized by a MPS and a MRS. An overview of the patient MPS
and MRS is presented in the figure below.
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The Coronary Intervention Study, CIS. is a multicentre, randomized, double-
blind. placebo-controlled study to investigate the effects of lipid-modifying
therapy on progression in 254 men with documented coronary artery dis-
ease (CAD) and hypercholesterolemia. Entry criteria were the presence of
at least 3 coronary stenoses of :::25% and a mean serum total cholesterol
1st angio 2nd angio 6-
(mm) Imm) (mm)
1.15±0.28 0.91 ±0.52* 0.24±0.47
1.71 ±0.50 1.61 ± 0.53* 0.10±0.31!
1.13±0.280.79±0.54* 0.34±0.51
1.18±027 113±0.38 005±0.301
1st angio 2nd anglo /'>.
(%) (%) (%)
IRS 66.2±6.6 72.8± 16.9* 6.6± 15.8
non~RS 44.6 ± 14.5 48.0 ± 15.8* 3.4 ± 12.2!
Com IRS 66.9±7.1 76.5± 16.3* 9.6± 17.2
Smo IRS 64.8 ± 5.3 65.5 ± 12.1 0.71 ± 10.61
Clinical syndrome FP(%) LP(%) P
Stable/asymptomatic (10) 9(90) 1 (10)
] NS] ]<001New or Crescendo (16) 9(56) 7 (44)
Rest Angina (21) 4(19) 17 (81) ] NSPost-MI (13) 2(15) 11 (85)
Albert VG. Bruschke. J. Wouter Jukema. Ad J. van Boven. Johan H.C. Reiber.
Egbert T. Bal. Aeilko H. Zwinderman. Kong I. Lie. REGRESS study group
Interuniversity Cardiology Institute, Utrecht The Netherlands
REGRESS is a double blind, placebo controlled multicenter study to assess
the effect of 2 year treatment with pravastatin 40 mg once daily on pro- and
regression of angiographically documented coronary artery disease in BB5
patients with a serum cholesterol between 4--8 mmol~ (155 and 310 mg/dl).
The REGRESS study comprises three blocks of patients: a percutaneous
coronary angioplasty, a coronary artery bypass grafting and a medical man-
agement group. Analysis of baseline and follow-up coronary arteriograms
was performed visually and by quantitative computer analysis (OCA). Primary
The Influence of Pravastatin on Progression and
Regression of Coronary Atherosclerosis in Men with
Normal or Mildly Raised Serum Cholesterol. Results
of the Regression Growth Evaluation Statin Study
(REGRESS)
Coronary thrombus on histologic analysis was present in 23/36 164%) of
LP vs. in 5/24 (21 %) of FP (p < 0.01). Coronary thrombus was present in
BB% and B2% of LP in rest angina and post MI respectively. Inflammatory
cells were noted in 12 LP and 2 FP (p = 0.02) - in 38% of both rest angina
and post MI specimens. Conclusions: Lipid rich plaque are very common
in rest angina and post MI. moderately common in crescendo or new on-
set and rare in stable angina. LP are usually associated with thrombus and
inflammation particularly in rest angina and post MI pts. These DCA tissue
analyses confirm and expanded on prior autopsy studies in acute syndromes
and support the pathogenetic link between unstable rest angina and acute
MI.
Despite clinical stabilization. IRS are unstable and at high risk for rapid pro-
gression to total occlusion, which is usually assoeiated with coronary events.
Data are mean ± SD. *p < 0.01 vs. 1st angio by paired t-test; !p < 0.05 vs. IRS. and I p <
0.01 vs. Com IRS by unpaired t-test. Com = complex. Smo = smooth
Samin K. Sharma. Billie Fyfe. Ram Bongu. Jeremy Asnes. Jonathan D. Marmur.
Thomas Cocke. Orlandino D. Almeida. John A. Ambrose. Mount Sinai Hospital. New
York. N.Y.
Several autopsy studies indicate that disrupted atherosclerotic plaques par-
ticularly those rich in lipid with associated thrombus. are the cause of acute
MI. Other plaques without disruption are fibrocellular without lipid. Although
unstable rest angina (UA) shares a common pathogenesis to acute MI. there
are little pathological data on plaque composition in UA. Directional Coronary
Atherectomy (DCA) provides the opportunity to study plaque composition in
UA. Methods: We prospectively analyzed the DCA tissue specimens of 60
pts with de novo culprit lesions for fibrocellular and lipid constituents by
hematoxylin & eosin and oil red 0 stains. A fibrous plaque (FP) was defined
as one which had predominantly fibrous and sclerotic tissue with no or min-
imallipid (0 or 1+ on scale of 3). A lipid plaque (LP) was defined as one with
moderate or high lipid (2 or 3+) content. The presence of inflammatory cells
and thrombus were also noted. Histopathology was analyzed independent
of clinical presentation.
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1768-61 Lipid Rich Plaques with Thrombus are Common In
Unstable Rest Angina: Observations from
Atherectomy Tissue Analysis
17691 The Effect of Lipid-Lowering Drugs on
Coronary Anatomy and Myocardial Ischemia
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(C) of :0:207 mg/dl after diet. Treatment with up to 40 mg simvastatin (S) or
placebo (P) o.d. included diet and - as a reserve medication: - colestyra-
mine, and was pursued for 2.3 years (S/P: 865/835 days). The two treat-
ment groups (see below) were comparable with respect to baseline van~
ables, e,g. average age (49.9/49.1 y), height(175.4/175,2 cm), weight(80.1 /80
kg), blood pressure (123,5/79.8 vs, ·123.1/78.6 mmHg). diastolic hyperten-
sion :0:90 mmHg (9.619.1%), fasting serum glucose :0:120 mg/dl (2.9/5.1%),
family history (47.1/48.0%), smoking (83.6/85.9), ventricular score (1.0/0.9).
coronary score (2.12/1.93 - vessel-disease), and lipid values, with a base-
line LDL-C of 163.8/166.7 mg/dl. Treatment resulted in significant changes of
serum lipids with a decrease of LDL-C by 33% and -1.5% in the Sand P
group, respectively. 204 (81%; 104/1001 patients had a second angiography.
Two primary end points were chosen: - the within-patient change in min-
imum diameter avenged over all assessable coronary segments (""'minD",
determined by quantitative analysis using the CAAS system), and - the vi-
sual Global Change Score ("GCS", Blankenhorn), and calculated according to
Bonferroni-Holme on a multiple significance level of 5%. The detailed results
will be presented.
Supported by MSD Sharp and Dohme, Munich, Germany
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1769-41 Lowering of Cholesterol With Simvastatln may
Prevent Development of Heart Failure In Patients
With Coronary Heart Disease
John Kjekshus, Terje Pedersen on behalf of the 4S Study Group. University of Oslo,
Oslo. Norway
While treatment of myocardial overload effectively reduces death from pro-
gression of heart failure, it is not known whether the retardation of progres-
sive coronary heart disease obtained with lipid lowering treatment will pre-
vent onset of heart failure. In the 4S trial 4444 patients without evidence
of heart failure were randomised to placebo (P), (n = 2221) or simvastatin
20--40 mg (S), (n = 2223) and followed for more than 5 years. In P 189 pa-
tients (8.5%) were diagnosed with heart failure during follow up vs. 147 in
S (6.2%) P < 0.003. Respectively 37 and 24 had occurrence of acute heart
failure. Heart failure patients were more likely to have higher triglyceride and
lower HDL than patients who did not develop congestive heart failure.
Conclusion: Long term prevention with simvastatin prevents occurrence
of heart failure in a cohort of patients with coronary heart disease, without
previous evidence of heart failure.
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1769-51 Reduction of Silent Myocardial Ischemia by
Pravastatln Additional to the Conventional Treatment
of Patients with Angina Pectoris
Ad J. van Boven, J. Wouter Jukema, Aeilko H. Zwinderman, Kong I. Lie. Albert
\I.G. Bruschke, REGRESS study group Interuniversity Cardiology Institute. Utrecht.
The Netherlands
With conventional treatment. including PTCA and CABG, complete abol-
ishment of Silent Myocardial Ischemia (SMI) is not attained. Cholesterol-
lowering therapy restores endothelial function and possibly lowers SM I me-
diated by disturbed vasomotion. We hypothesized that pravastatin 40 mg (PI
in addition of conventional therapy may reduce SMI and studied its 2 year
treatment effect in 339 patients from the REGRESS study, using 48 hour am-
bulatory ECG's. In this placebo controlled study only patients with angina
pectoris, documented coronary artery disease and a cholesterol between 4
and B mmolll are included. During Holter anti-ischemic medication was con-
tinued.
Results: At baseline (B) 28% of the patients had SMI and at follow up (F)
15%. A pronounced reduction of Pwas observed in the development of new
SMI in the group of patients with beta blockers (N = 141) at both B + F:
compared to placebo 7 patients less had new SMI (p = 0.05, Chi-Square) In
the group of patients (N = 173) taking nitrates 10 patients less had new SMI,
(p = 0.01). Also patients with triple anti-anginal medication IN = 72) at B +
F showed a beneficial effect of P on SMI (5 pts.less, p = 0.05). P reduced
number of ischemic episodes, duration of ischemia and ischemic burden.
Without the adjustment for concomitant medication the effect of P was not
significant.
Conclusion: Pravastatin causes an additional reduction of silent myocardial
ischemia in angina pectoris patients, who develop ischemia despite beta
blockers, nitrates or triple medication. A new anti-ischemic mode of action
of pravastatin in this subset is suggested, possibly by improving endothelial
function.
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Inhibitory Effect of Lovastatin on Human Coronary
Smooth Muscle Cell Proliferation
Vidya S. Banka, Peter S. Fail, Vasundhra Sharma Episcopal Heart Institute, Episcopal
Hospital. Philadelphia, PA
Longterm administration of lipid lowering agents has been shown to cause
regression of coronary atherosclerosis. To evaluate the mechanism of such
regression, we studied the effect of Lovastatin (HMG coenzyme A reductase
inhibitor) on the smooth muscle cells cultured from atherosclerotic plaque
obtained from 5 human coronary arteries undergoing directional coronary
atherectomy for de novo lesions. Arterial smooth muscle cell lines were cre-
ated by 3-5 passages. These cells were then placed at a density of 3000
cells/ml in M-199 medium with 10% fetal bovine serum. They were exposed
to Lovastatin at varying concentrations between 10-9 to 10-4 M. The coro-
nary arterial smooth muscle cells were inhibited in a dose dependent man-
ner. The table below shows the actual cell counts at various concentrations
of Lovastatin in the 5 patients.
Effect of Lovastatin on smooth muscle cell proliferation
PT Control Mitogen 10-9 10-8 10-7 10-6 10-5 10-4 M
J.B. 2575 5216 4325 3875 3320 2975 2575 1901
M.P 2879 4390 4125 3979 3629 3098 2095 1971
I.H. 2389 3613 3368 3153 2841 2221 2006 1696
M.L. 2900 5938 4817 3909 3199 2729 2072 1092
we 2830 3729 3210 2710 2093 1773 1292 934
Mean 2715 4581 3969 3525 3016 2559 2008 1519
Conclusion: HMG Coenzyme A reductase inhibitor Lovastatin has a strong
antiporliferative effect on human coronary smooth muscle cells. These ob-
servations suggest that antiproliferative effect of Lovastatin may be respon-
sible for causing regression of atherosclerotic lesions in addition to its lipid
lowering effects.
Calcium Regulation of Animal and Human
Cardiac Muscle
Tuesday, March 21,1995,4:00 p.m.-5:30 p.m.
Ernest N. Morial Convention Center, Room 21
4:00
1770-1 I Exogenously Administered Growth Hormone and
IGF-1 Alter Intracellular Calcium Handling and
Enhance Cardiac Performance
Hinrik Stromer, Antonio Cittadini, Pamela S. Douglas. James P. Morgan. Beth Israel
Hospital and Harvard Medical School, Boston, MA
To further elucidate the mechanisms by which growth hormone (GH) and
IGF-l modulate cardiac function, we studied isolated, isovolumic, buffer-
perfused rat hearts after 4 weeks of treatment with high doses of GH, IGF-l
or combination of both (G + I). Flow rate was 10 mllmin/g heart wt.. baseline
perfusate Ca2+ was 1.0 mmoill. Functional parameters including systolic and
diastolic pressure (Psys, Pdias' mmHg), maximal +dP/dt/DevP (sec-1) and
(calculated) peak systolic circumferential wall stress (asys, kdyn/m2) were
measured at 50% of the intracardiac balloon volume at which maximal devel-
oped pressure (DevP) occurred. EC50 (/tmolll) of the force Ca2+ relationship
and maximum Ca2+ activated force lasysmx, kdyn/cm2) were assessed by
stepwise increase of Ca2+ in the perfusate and plotting asys vs. intracellu-
lar peak systolic Ca2+ measured by the aequorin bio-Iuminescence method.
Results at baseline and Ca2+ response were as follows:
Psys asys +dPldt/DevP EC50 usysmx
Control 139 ± 5# 68± 5 15.4±0.1 0.67 ± 001 78± 5
IGF-' 169 ± 6#* 68 ± 2 17.7 ± 0.2#* 0.73 ±0.02* 103 ± 4*
GH 162 ± 5#* 67 ± 3 16.5 ± 0.2* 0.74 ± 0.01* 107 ± 4*
G + I 153 ± 4* 69 ± 3 156 ± 0.3 0.72 ± 0.02' 106 ± 2*
Data are mean ± SEM: *p < 0.05 vs. control. #vs. G + I
Pdias. Casys. Cadias. shape and duration of the Ca2+ transient were not in-
fluenced by the treatments. All treatmenls caused a similar increase of heart
wt. although the heart wt. to body wt. ratio remained unchanged. asys was
unchanged by the treatments despite increasing Psys , suggesting a concen-
lric growth pattern. In addition to the increased Psys enhanced systolic per-
formance was demonstrated by an increased asysmx, although this effect is
not seen on asys at baseline due to an increased EC50 .
These data support the hypothesis, that both IGF-l and GH have a direct
effect on cardiac performance by influencing geometry and maximum Ca2+
activated force capacity.
